Your browser doesn't support javascript.
loading
MyD88 and its divergent toll in carcinogenesis.
Salcedo, Rosalba; Cataisson, Christophe; Hasan, Uzma; Yuspa, Stuart H; Trinchieri, Giorgio.
Afiliação
  • Salcedo R; Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 217023, USA.
Trends Immunol ; 34(8): 379-89, 2013 Aug.
Article em En | MEDLINE | ID: mdl-23660392
ABSTRACT
Toll-like and interleukin-1 (IL-1) family receptors recognize microbial or endogenous ligands and inflammatory mediators, respectively, and with the exception of Toll-like receptor 3 (TLR3), signal via the adaptor molecule myeloid differentiation factor 88 (MyD88). MyD88 is involved in oncogene-induced cell intrinsic inflammation and in cancer-associated extrinsic inflammation, and as such MyD88 contributes to skin, liver, pancreatic, and colon carcinogenesis, as well as sarcomagenesis. MyD88 is also protective, for example in oncogenic virus carcinogenesis or, acting downstream of IL-18R to strengthen mucosal repair, in azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colon carcinogenesis. Here, we discuss the mechanisms of the divergent effects of MyD88 and the balance of its protumor role in cancer-enhancing inflammation and immunity and its antitumor role in tissue homeostasis, repair, and immunity against the tumor or oncogenic pathogens.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transformação Celular Neoplásica / Fator 88 de Diferenciação Mieloide Limite: Animals / Humans Idioma: En Revista: Trends Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transformação Celular Neoplásica / Fator 88 de Diferenciação Mieloide Limite: Animals / Humans Idioma: En Revista: Trends Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Estados Unidos